Overview
Development Programs
Differentiated prodrug candidates initially targeting established IBD market with potential to address shortcomings of existing therapies
❯ More
Your tooltip content goes here
❯ More
Your tooltip content goes here
PALI-2108
Indication
Ulcerative Colitis
Status
IND/CTA-Enabling
Highlights
IND/CTA-enabling tox studies completed and CTA submitted
Rapidly advancing towards first patient dosed in Phase 1 of healthy and UC patients in 2024
PALI-1908
Indication
Fibro Stenotic Crohn’s Disease
Status
Discovery
Highlights
Significant overlap with PALI-2108
POC for fibrosis pathway engagement completed
PDE4 Platform
Precision Medicine Approach
Sign Up For Alerts